5-LOX-IN-8 is a 5-LOX inhibitor with anti-inflammatory properties. It suppresses IL-6, IL-1β, TNF-α, and IFN-γ in macrophages and reduces IL-8 secretion in SW480 cells. Additionally, 5-LOX-IN-8 decreases the disease activity index in DSS colitis models. This compound is applicable for research in inflammatory bowel disease (IBD).

5-LOX-IN-8 (Compound 18d) demonstrates cytotoxic effects on THP-1 cells (IC 50: 37.65 μM) and SW 480 cells (IC 50: 14.37 μM) at concentrations ranging from 0.3 to 50 μM over 24 hours. At 10 μM for 5 minutes, it inhibits human recombinant 5-LOX by 40.65% and reduces NO production in SW480 cells by 38.85%. When pre-treated at 10 μM for 1 hour followed by co-culture with LPS for 24 hours, 5-LOX-IN-8 suppresses the LPS-induced production of IL-6 (93.98%), IL-1β (19.41%), TNF-α (45.97%), and IFN-γ (66.61%) in THP-1 macrophages.

5-LOX-IN-8 (Compound 18d) at a dosage of 30 mg/kg reduces disease activity in a 5% DSS-induced mouse colitis model.